Prosecution Insights
Last updated: August 07, 2026

Tonix Pharma Limited

7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
3
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (14%)
6
Medium (86%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (14%)
Double-patenting + other5 (71%)
Multi-statute (no §101)1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TAYLOR, LIA ELAN 1 64.1% +28.6%
BARSKY, JARED 1 50.3% +23.1%
CHONG, YONG SOO 1 43.7% +41.7%
NEAGU, IRINA 1 46.8% +57.5%
MIDDLETON, DANAYA L 1 46.1% +54.1%
CRAIGO, WILLIAM A 1 49.2% +38.2%
BAEK, BONG-SOOK 1 41.7% +69.8%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17226058 CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION CRAIGO, WILLIAM A 4d overdue

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17226058 CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION CRAIGO, WILLIAM A 4d overdue
18265525 CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA CHONG, YONG SOO 26d
17623710 ANTI-CD154 ANTIBODIES AND USES THEREOF MIDDLETON, DANAYA L 70d
18271098 METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES TAYLOR, LIA ELAN
18212500 CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) BARSKY, JARED
18037815 CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER NEAGU, IRINA
17269106 METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER BAEK, BONG-SOOK

Top Art Units

Art UnitApps
1641 1
1628 1
1623 1
1629 1
1674 1
1615 1
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18271098 METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES TAYLOR, LIA ELAN 1641 §103§112DP Non-Final OA Pending Jul 06, 2023
18212500 CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) BARSKY, JARED 1628 §103DP Final Rejection Pending Jun 21, 2023
18265525 CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA CHONG, YONG SOO 1623 §103Other Non-Final OA 26d Pending Jun 06, 2023
18037815 CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER NEAGU, IRINA 1629 §103DP Final Rejection Pending May 19, 2023
17623710 ANTI-CD154 ANTIBODIES AND USES THEREOF MIDDLETON, DANAYA L 1674 §103§112DPOther Non-Final OA 70d Pending Dec 29, 2021
17226058 CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION CRAIGO, WILLIAM A 1615 §103§112Other Final Rejection 4d overdue Pending Apr 08, 2021
17269106 METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER BAEK, BONG-SOOK 1611 §103DP Final Rejection Pending Feb 17, 2021

Managing Tonix Pharma Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month